Literature DB >> 31274168

The Use of L2 and L3 Lumbar Sympathetic Blockade for Cancer-Related Pain, an Experience and Recommendation in the Oncologic Population.

Matthew A Spiegel1, Lee Hingula1, Grant H Chen1, Aron Legler1, Vinay Puttanniah1, Amitabh Gulati1.   

Abstract

OBJECTIVE: The sympathetic nervous system has a recognized role in transmission of pain, and the lumbar sympathetic blockade is intended to provide analgesia. We share our experiences of lumbar sympathetic blockade in the treatment of cancer-related pain.
METHODS: We performed a retrospective analysis of patients with cancer-related pain in the back, abdomen, pelvis, or legs treated at Memorial Sloan Kettering Cancer Center between 2000 and 2018 undergoing lumbar sympathetic blockade at L2 or L3. Blocks were accomplished by injection of local anesthetic or local anesthetic with steroid under fluoroscopy. We measured numerical rating scale scores, percent relief, and relief time. The primary end point was defined as "effective" or "ineffective" pain relief. Effective pain relief was defined as ≥30% relief for at least one day.
RESULTS: We identified 124 data points of lumbar sympathetic blockade at L2 or L3, of which 57 were with complete data and used for analysis. Peri-injection, 42 data points had active disease whereas 15 were in remission. Lumbar sympathetic blockade was 67% effective in the back pain cohort, 82% effective in the abdominopelvic pain cohort, and 75% effective in the leg pain cohort. Seventeen data points went on to neurolysis, two to neuromodulation, and eight to intrathecal pump implantation.
CONCLUSIONS: Lumbar sympathetic blockade is effective for back, abdominopelvic, and leg pain related to cancer and its treatments. Future research should be aimed at refining its role within multimodal pain management.
© 2019 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cancer Pain; Lumbar Sympathetic Block

Year:  2020        PMID: 31274168      PMCID: PMC7761528          DOI: 10.1093/pm/pnz142

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  17 in total

1.  Dexamethasone added to bupivacaine prolongs duration of epidural analgesia.

Authors:  Bahman Naghipour; Dawood Aghamohamadi; Rasoul Azarfarin; Moussa Mirinazhad; Eissa Bilehjani; Dorosti Abbasali; Samad E J Golzari
Journal:  Middle East J Anaesthesiol       Date:  2013-02

Review 2.  Opioids for cancer pain - an overview of Cochrane reviews.

Authors:  Philip J Wiffen; Bee Wee; Sheena Derry; Rae F Bell; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-07-06

3.  Evidence-based interventional pain medicine according to clinical diagnoses. 16. Complex regional pain syndrome.

Authors:  Frank van Eijs; Michael Stanton-Hicks; Jan Van Zundert; Catharina G Faber; Timothy R Lubenow; Nagy Mekhail; Maarten van Kleef; Frank Huygen
Journal:  Pain Pract       Date:  2010-08-27       Impact factor: 3.183

4.  The effects of early or late neurolytic sympathetic plexus block on the management of abdominal or pelvic cancer pain.

Authors:  Raquel de Oliveira; Marlene P dos Reis; Wiliam A Prado
Journal:  Pain       Date:  2004-07       Impact factor: 6.961

5.  Comparison of histopathological effects of perineural administration of bupivacaine and bupivacaine-dexmedetomidine in rat sciatic nerve.

Authors:  Elham Memari; Mohammad-Ali Hosseinian; Ali Mirkheshti; Ali Arhami-Dolatabadi; Mojtaba Mirabotalebi; Mohsen Khandaghy; Yahya Daneshbod; Leila Alizadeh; Sadegh Shirian
Journal:  Exp Toxicol Pathol       Date:  2016-09-17

Review 6.  Sympathetic blocks: the evidence.

Authors:  Miles Day
Journal:  Pain Pract       Date:  2008 Mar-Apr       Impact factor: 3.183

7.  Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.

Authors:  Thomas J Smith; Peter S Staats; Timothy Deer; Lisa J Stearns; Richard L Rauck; Richard L Boortz-Marx; Eric Buchser; Elena Català; David A Bryce; Patrick J Coyne; George E Pool
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544

Review 8.  Percutaneous destructive pain procedures on the upper spinal cord and brain stem in cancer pain: CT-guided techniques, indications and results.

Authors:  Y Kanpolat
Journal:  Adv Tech Stand Neurosurg       Date:  2007

Review 9.  Corticosteroids for the management of cancer-related pain in adults.

Authors:  Alison Haywood; Phillip Good; Sohil Khan; Aurelia Leupp; Sue Jenkins-Marsh; Kirsty Rickett; Janet R Hardy
Journal:  Cochrane Database Syst Rev       Date:  2015-04-24

Review 10.  Dexamethasone as an adjuvant to peripheral nerve block.

Authors:  Carolyne Pehora; Annabel Me Pearson; Alka Kaushal; Mark W Crawford; Bradley Johnston
Journal:  Cochrane Database Syst Rev       Date:  2017-11-09
View more
  1 in total

Review 1.  Interventional Therapies for Pain in Cancer Patients: a Narrative Review.

Authors:  David Hao; Shawn Sidharthan; Juan Cotte; Mary Decker; Mariam Salisu-Orhurhu; Dare Olatoye; Jay Karri; Jonathan M Hagedorn; Peju Adekoya; Charles Odonkor; Amitabh Gulati; Vwaire Orhurhu
Journal:  Curr Pain Headache Rep       Date:  2021-05-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.